metricas
covid
Buscar en
Gastroenterología y Hepatología
Toda la web
Inicio Gastroenterología y Hepatología Artificial intelligence for dysplasia detection during surveillance colonoscopy ...
Journal Information
Share
Share
Download PDF
More article options
Visits
132
Original article
Available online 4 June 2024
Artificial intelligence for dysplasia detection during surveillance colonoscopy in patients with ulcerative colitis: A cross-sectional, non-inferiority, diagnostic test comparison study
Inteligencia artificial en la detección de displasias durante la colonoscopia de vigilancia en pacientes con colitis ulcerosa de larga evolución: estudio de comparación de pruebas diagnósticas, transversal, de no inferioridad
Visits
132
Antonio López-Serranoa,b,
Corresponding author
anlopezs@comv.es

Corresponding author.
, Alba Vocesa, José Ramón Lorentea, Francisco José Santonjac, Angela Algarraa, Patricia Latorrea, Pablo del Pozoa, José María Paredesa
a Gastroenterology Department, Hospital Universitari Dr. Peset, Valencia, Spain
b Department of Medicine, Universitat de Valencia, Valencia, Spain
c Statistics and Operational Research Department, Universitat de Valencia, Valencia, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (5)
Table 1. Inclusion and exclusion criteria.
Table 2. Clinical characteristics of patients in 52 patients at inclusion into the study.
Table 3. Characteristics of the endoscopic findings and exploration time.
Table 4. Distribution of lesions (‘per lesion’ analysis) and distribution of patients (‘per patient’ analysis) in relation to the presence or absence of dysplasia and the type of procedure.
Table 5. Characteristics of suspicious resected lesions referred for histological analysis and not detected by VCE or CADe.
Show moreShow less
Abstract
Background and study aim

High-definition virtual chromoendoscopy, along with targeted biopsies, is recommended for dysplasia surveillance in ulcerative colitis patients at risk for colorectal cancer. Computer-aided detection (CADe) systems aim to improve colonic adenoma detection, however their efficacy in detecting polyps and adenomas in this context remains unclear. This study evaluates the CADe Discovery™ system's effectiveness in detecting colonic dysplasia in ulcerative colitis patients at risk for colorectal cancer.

Patients and methods

A prospective cross-sectional, non-inferiority, diagnostic test comparison study was conducted on ulcerative colitis patients undergoing colorectal cancer surveillance colonoscopy between January 2021 and April 2021. Patients underwent virtual chromoendoscopy (VCE) with iSCAN 1 and 3 with optical enhancement. One endoscopist, blinded to CADe Discovery™ system results, examined colon sections, while a second endoscopist concurrently reviewed CADe images. Suspicious areas detected by both techniques underwent resection. Proportions of dysplastic lesions and patients with dysplasia detected by VCE or CADe were calculated.

Results

Fifty-two patients were included, and 48 lesions analyzed. VCE and CADe each detected 9 cases of dysplasia (21.4% and 20.0%, respectively; p=0.629) in 8 patients and 7 patients (15.4% vs. 13.5%, respectively; p=0.713). Sensitivity, specificity, positive and negative predictive values, and diagnostic accuracy for dysplasia detection using VCE or CADe were 90% and 90%, 13% and 5%, 21% and 2%, 83% and 67%, and 29.2% and 22.9%, respectively.

Conclusions

The CADe Discovery™ system shows similar diagnostic performance to VCE with iSCAN in detecting colonic dysplasia in ulcerative colitis patients at risk for colorectal cancer.

Keywords:
Ulcerative colitis
Colonoscopy
Colitis-associated neoplasm
Virtual chromoendoscopy
Artificial intelligence
Resumen
Antecedentes y objetivo

La cromoendoscopia virtual (CEV) de alta definición se recomienda para la vigilancia de displasias en pacientes con colitis ulcerosa y riesgo de cáncer colorrectal. Los sistemas de detección por computadora (CADe) buscan mejorar la detección de adenomas colónicos, pero su eficacia en este contexto aún no está definida. Se evalúa la eficacia del sistema CADe DiscoveryTM para detectar displasias colónicas en estos pacientes.

Pacientes y métodos

Estudio prospectivo de comparación de pruebas diagnósticas de no inferioridad, transversal, en pacientes con colitis ulcerosa sometidos a colonoscopia de vigilancia entre enero de 2021 y abril de 2021. Se realizó una CEV con iSCAN 1 y 3 con realce óptico. Un endoscopista examinó el colon en secciones, mientras otro revisó las imágenes CADe. Las áreas sospechosas detectadas por ambas técnicas fueron resecadas. Se calcularon las proporciones de lesiones displásicas y de pacientes con displasia detectados por VCE o CADe.

Resultados

Se analizaron 48 lesiones en 52 pacientes. VCE y CADe detectaron 9 casos de displasia cada uno (21,4 y 20,0%, respectivamente; p=0,629) en 8 y 7 pacientes (15,4 vs. 13,5%, respectivamente; p=0,713). Sensibilidad, especificidad, valores predictivos positivo y negativo, y precisión diagnóstica para detectar displasia utilizando VCE o CADe fueron del 90 y 90%, 13 y 5%, 21 y 2%, 83 y 67%, y 29,2 y 22,9%, respectivamente.

Conclusiones

El sistema CADe DiscoveryTM muestra un rendimiento diagnóstico similar al de CEV con iSCAN en la detección de displasias colónicas en pacientes con colitis ulcerosa de riesgo de cáncer colorrectal.

Palabras clave:
Colitis ulcerosa
Colonoscopia
Neoplasia asociada a colitis
Cromoendoscopia virtual
Inteligencia artificial

Article

These are the options to access the full texts of the publication Gastroenterología y Hepatología
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Gastroenterología y Hepatología

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos